TY - JOUR
T1 - Effect of Atorvastatin (80 mg/day) versus Pravastatin (40 mg/day) on arterial remodeling at coronary branch points (from the REVERSAL study)
AU - Nicholls, Stephen J.
AU - Tuzcu, E. Murat
AU - Schoenhagen, Paul
AU - Sipahi, Ilke
AU - Crowe, Tim
AU - Kapadia, Samir
AU - Nissen, Steven E.
N1 - Funding Information:
The Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) study was funded by Pfizer, New York, New York. Dr. Nicholls was supported by a Ralph Reader Overseas Research Fellowship from the National Heart Foundation of Australia, Melbourne, Australia.
PY - 2005/12/15
Y1 - 2005/12/15
N2 - The effect of moderate and intensive lipid lowering on plaque progression and arterial remodeling at coronary branch points was investigated. Intensive (+1 ± 19.6%), but not moderate (+4.1 ± 15.1%), lipid lowering prevented an increase in plaque area at the branch points. The 2 strategies were associated with increased areas of the lumen (+7.6% to 9.4%) and external elastic membrane (+9.6% to 10.8%). In contrast, there was no significant change in plaque, lumen, and/or external elastic membrane areas at the nonbranch point site. These results suggest that intensive lipid lowering can have a dramatic effect on atheroma-prone regions and that remodeling in response to changes in plaque is a heterogenous process.
AB - The effect of moderate and intensive lipid lowering on plaque progression and arterial remodeling at coronary branch points was investigated. Intensive (+1 ± 19.6%), but not moderate (+4.1 ± 15.1%), lipid lowering prevented an increase in plaque area at the branch points. The 2 strategies were associated with increased areas of the lumen (+7.6% to 9.4%) and external elastic membrane (+9.6% to 10.8%). In contrast, there was no significant change in plaque, lumen, and/or external elastic membrane areas at the nonbranch point site. These results suggest that intensive lipid lowering can have a dramatic effect on atheroma-prone regions and that remodeling in response to changes in plaque is a heterogenous process.
UR - http://www.scopus.com/inward/record.url?scp=29044447332&partnerID=8YFLogxK
U2 - 10.1016/j.amjcard.2005.07.085
DO - 10.1016/j.amjcard.2005.07.085
M3 - Article
C2 - 16360349
AN - SCOPUS:29044447332
VL - 96
SP - 1636
EP - 1639
JO - American Journal of Cardiology
JF - American Journal of Cardiology
SN - 0002-9149
IS - 12
ER -